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Abstract
Background:  Complementary therapies are widespread but controversial. We aim to provide a
comprehensive collection and a summary of systematic reviews of clinical trials in three major
complementary therapies (acupuncture, herbal medicine, homeopathy). This article is dealing with
herbal medicine. Potentially relevant reviews were searched through the register of the Cochrane
Complementary Medicine Field, the Cochrane Library, Medline, and bibliographies of articles and
books. To be included articles had to review prospective clinical trials of herbal medicines; had to
describe review methods explicitly; had to be published; and had to focus on treatment effects.
Information on conditions, interventions, methods, results and conclusions was extracted using a
pre-tested form and summarized descriptively.
Results:  From a total of 79 potentially relevant reviews pre-selected in the screening process 58
met the inclusion criteria. Thirty of the reports reviewed ginkgo (for dementia, intermittent
claudication, tinnitus, and macular degeneration), hypericum (for depression) or garlic preparations
(for cardiovascular risk factors and lower limb atherosclerosis). The quality of primary studies was
criticized in the majority of the reviews. Most reviews judged the available evidence as promising
but definitive conclusions were rarely possible.
Conclusions:  Systematic reviews are available on a broad range of herbal preparations prescribed
for defined conditions. There is very little evidence on the effectiveness of herbalism as practised
by specialist herbalists who combine herbs and use unconventional diagnosis.
Introduction
In this second part of our series on systematic reviews in
complementary therapies we report our findings on
herbal medicines. Herbal medicines (defined as prepara-
tions derived from plants and fungi, for example by alco-
holic extraction or decoction, used to prevent and treat
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almost any culture [1]. In industrialized countries herbal
drugs and supplements are an important market. Some
countries like Germany have a long tradition in the use of
herbal preparations marketed as drugs and figures for
prescriptions and sales are stable or slightly declining
[2]. In the US and the UK herbal medicinal products are
marketed as "food supplements" or "botanical medi-
cines". In recent years sales of such products have been
increasing strongly in these countries [3,4]. In the Third
World herbs are mainly used by traditional healers [5].
Methods
A detailed description of the methods used in this review
of reviews is given in the first part of this series [6]. For
searches in Medline 50 single plant names and the 'ex-
ploded' term 'medicinal plants' were combined with the
standard search strategy for systematic reviews. As a
specific intervention-related inclusion criterion we re-
quired that reports reviewed prospective (not necessarily
controlled) clinical trials of substances extracted from
plants in humans. Reviews dealing with single substanc-
es (e.g., artemisin derivatives) derived from plants were
excluded on the grounds that such agents are compara-
ble to conventional drugs. Disease-oriented reviews in-
cluding a variety of interventions were included only if
they reviewed at least 4 herbal medicine trials.
Results
From a total of 79 potentially relevant reviews preselect-
ed in the literature screening process, 58 (published in
65 papers) met the inclusion criteria [7–71]. Eleven re-
ports were not truly systematic reviews (not meeting in-
clusion criterion 2) [72–82], 5 dealt with isolated
substances of plant origin [83–87] and 4 were excluded
for other reasons (one disease- focused review with less
than 4 herbal medicine trials [88], one review not on pre-
ventative or therapeutic use [89], two reviews not truly
herbal medicine [90,91]).
More than half of the reports reviewed gingko, hyperi-
cum or garlic preparations. No less than 13 systematic re-
views dealed with ginkgo (Ginkgo biloba) extracts (see
table 1). Seven of these reviewed trials (total number of
trials covered in any of the reviews 15) in patients with
intermittent claudication [7–13]. Most of these reviews
concluded that ginkgo extracts were significantly more
effective than placebo in increasing measures like walk-
ing distance but the clinical relevance of the effects was
felt to be moderate by some reviewers. The five reviews
dealing with dementia and cerebral insufficiency (total
number of trials included about 50) all draw positive
conclusions [13–17]. However, many of the older trials
were in patients with minor cognitive impairment and
more evidence is needed to decide whether ginkgo ex-
tracts have clinically relevant beneficial effects in more
severe forms of dementia. Finally, one review found that
ginkgo extracts might be effective in the treatment of tin-
nitus [18] and another found insufficient evidence for ef-
ficacy in patients with macular degeneration [19].
The effectiveness of St. John's wort (Hypericum perfo-
ratum) extracts in depression was investigated in nine
reviews [20–30] (total number of trials covered 29; see
table 2). Mainly due to slight differences in the inclusion
criteria (for example, restriction to trials with a mini-
mum of 6 weeks observation or with a minimum quality
score) the respective study collections differed to a con-
siderable amount. However, the conclusions were very
similar. Hypericum extracts have been shown to be supe-
rior to placebo in mild to moderate depressive disorders.
There is growing evidence that hypericum is as effective
as other antidepressants for mild to moderate depres-
sion and causes fewer side effects but further trials are
still needed to establish long-term effectiveness and safe-
ty.
Eight reviews have been performed on garlic (Allium
sativum) for cardiovascular risk factors [31–38] (total
number of trials covered about 50) and lower limb
atherosclerosis [39] (see table 2). A modest short-term
effect over placebo on lipid-lowering seems to be estab-
lished but the clinical relevance of these effects is uncer-
tain. Data from randomised trials on cardiovascular
mortality are not available. Effects on blood pressure
seem to be at best minor. The available results on fibri-
nolytic activity and platelet aggregation are promising
but insufficient to draw clear conclusions. A specific
problem in research on garlic is the great variety of garlic
preparations used: the exact content of bioactive ingredi-
ents in these is often unclear.
Three reviews (covering a total of about 30 trials) have
been performed on preparations containing extracts of
Echinacea (Echinacea purpurea, pallida or angustifo-
lia), two of which by the same study group [40–43]. The
results suggest that Echinacea preparations may have
some beneficial effects mainly in the early treatment of
common colds. Similar to garlic a major problem is the
high variaton of bioactive compounds between different
Echinacea preparations. Cranberries (Vaccinium mac-
rocarpon) for urinary tract infections [44,45], mistletoe
(Viscum album) for cancer [46–48], peppermint (Men-
tha piperita) oil for irritable bowel syndromes [49,50]
and saw palmetto (Serenoa repens) for benign prostate
hyperplasia [51–53] have each been subject to two re-
views. For saw palmetto there is good evidence for effica-
cy over placebo while for the other three the data are
inconclusive (see table 3).
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Features
Author Year Indication Intervention Comparisons Studies 1/2/3/ Results Author's Conclusion
4/5
Ginkgo (Ginkgo biloba)
Pittler 2000
[7]
intermittent
claudication
ginkgo placebo 8 RCT y/y/y/
y/y
Increase of pain-free walking 
distance over placebo after 
12or 24 weeks 34 m (95%CI 
26–43 m)
Evidence for a modest 
benefit of uncertain clinical 
relevance
Moher 2000
[8]
intermittent
claudication
ginkgo* placebo 5 RCT y/y/y/
n/y
Increase of pain-free walking
distance over placebo after 24 
weeks 32 m (95%CI 14–50 m)
Inconsistent results from 
the few available small 
studies do not allow firm 
conclusions
Ernst 96 [9] intermittent
claudication
ginkgo 
extract
EGb761
placebo,
other drugs
10
RCT/CCT
p/ p/ n/
n/n
Most studies low quality. In-
crease of walking distance com-
pared to placebo 24 to 160 
m. At least similar effectiveness 
compared to other drugs.
 
Available evidence promis-
ing but further high quality 
research needed. 
Schneider 92 
[10]
intermittent
claudication
ginkgo placebo,
other 
treatment
7 RCT/CCT 
(vs. plac.), 2 
RCT/CCT 
(other)
?/n/n/
 y/y
mean effect size d = 0.75 
(95%CI 0.44–1.07) over placebo
Effectiveness over placebo 
clearly shown
Letzel 92
[11]
intermitent 
claudication
ginkgo ex-
tract EGb 
761
ginkgo vs.
plac., 
pentoxifyllin
vs. plac. 
5 RCT 
ginkgo 
9 RCT 
pentoxifyllin
?/p/n/
 y/y
Pooled increase of walking
distance: 45% over placebo for 
gingko and 57% for pentoxifyllin
Ginkgo extract EGb761 
more effective than place-
bo and similarly effective 
as pentoxifyllin
Kleijnen 91 intermittent ginkgo ginkgo vs. 15 y/y/y/ Many trials low quality. All trials Ginkgo seems effective for
[12] claudication plac., RCT/CCT n/n with positive results. Evidence intermittent claudication 
but further
pentoxifyllin (ginkgo), 5 similar as for pentoxifyllin high quality studies are 
needed
vs. placebo RCT/CCT
pentoxif.
Weiss 91 cerebral 
ins.,
ginkgo placebo 17RCT/
CCT
?/p/p/ 10 of 12 interpretable trials on Effectiveness for both con-
ditions
[13] intermittent extract (cerebral n/n cerebral insufficieny and all 4 biometrically shown
claudication EGb761 ins.), 8 interpretable trials on
RCT/CCT intermittent claudication with
significant positive results
Ernst 99 [14] dementia ginkgo placebo 9 RCT y/y/y/ Results collectively suggest Encouraging findings war-
ranting
y/n that ginkgo is more effective for large scale trials
dementia than placebo
Oken 98 
[15]
Alzheimer 
dementia
ginkgo placebo 4 RCT y/y/n/ Significant effect over placebo Clinical relevance of the 
observed
y/y for cognitive function (Hedges effects has to be confirmed 
in
g= 0.41, 95%CI 0.22–0.61) further research
Hopfen-
müller
cerebral ginkgo placebo 10 RCT, 1 n/ n/ n/ Global response (based on Ginkgo extract superior 
to placebo
94 [16] insufficiency extract LI CCT y/y symptom scores): OR 1.98
1370 (95%C11.39–2.57) in favour of
Ginkgo
Kleijnen 92 cerebral ginkgo ginkgo vs. 40 RCT/ y/y/y/ Many trials low quality. Virtually Ginkgo seems effective for
[17] insufficiency plac. CCT n/n all trials reported positive cerebral insufficiency but 
further
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(Aloe vera) [54], artichoke (Cynara scolymus) leave ex-
tract [55], evening primrose (Oenothera biennis) oil
[56], feverfew (Tanacetum parthenium) [57], ginger
(Zingiber officinialis) [58], ginseng (Panax ginseng)
[59], horse chestnut (Aesculus hippocastanum) seeds
[60], kava (Piper methysticum) [61], milk thistle (Sily-
bum marianum) [62], a fixed combination of three herb-
al extracts [63], rye-grass pollen (Secale cereale) extract
[64,65], tea tree (Melaleuca alternafolia) oil [66], and
valerian (Valehana officinalis) root [67] (see table 4).
The only review which focused on a herbal intervention
which is not marketed as a drug or food supplement was
on cabbage leaves for breast engorgement and included
a single small-scale trial [68]. Chinese herbal therapy for
atopic eczema [69] and a variety of herbs for lowering
blood glucose [70] and for analgesic and anti-inflamma-
tory purposes [71] have also been reviewed. For some of
these herbal preparations the evidence is promising but
further studies are considered necessary to establish ef-
ficacy in almost every case.
hydergine (ginkgo), 4 results. Evidence similar as for high quality studies are 
needed
vs. plac. RCT/CCT hydergine
(hydergine)
Ernst 99 [18] tinnitus ginkgo placebo, 5 RCT y/y/y/ 3 trials favour ginkgo over Results suggest that ex-
tracts of
other y/n placebo, 1 no difference, in one ginkgo biloba are effective 
in
treatment (1 trial ginkgo better than another treating tinnitus
trial) treatment
Evans 2000 macular ginkgo placebo 1 RCT y/y/y/ one small trial reporting Insufficient evidence to
[19] degenera-
tion
y/- improvement recommend ginkgo for 
age-related
macular degeneration
Features: 1 = comprehensive search, 2 = explicit inclusion criteria, 3 = formal quality assessment, 4 = summary of results for each included study, 5 
= meta-analysis; y = yes, p = partly, n = no, - = not applicable, ? = unclear review on all pharmacologic treatments for the respective condition RCT 
= randomized controlled trials, CCT = non-randomized controlled trials, CS = cohort studies, UCS = uncontrolled studies; OR = odds ratio, RR = 
rate ratio
Table 1: Systematic reviews of clinical trials of ginkgo biloba extracts (Continued)
Table 2: Systematic reviews of clinical trials of hypericum and garlic preparations
Features
Author Indication Intervention Comparisons Studies 1/2/3/ Results Author's Conclusion
Year 4/5
St John's wort (Hypericum perforatum)
Gaster depression hypericum placebo and 8 RCT p/y/p/ 4 placebo-controlled trials with Data suggest that hypericum is
2000 [20] antidepres-
sants
y/n positive results, in 4 trials superior to placebo, insuf-
fcient
standard antidepr. tended to be evidence re equivalence with
slightly better antidepressants
Williams depression hypericum placebo and 14 RCT y/y/n/ Treatment response: RR 1.9 Data suggest that hypericum is
2000 & (and other antidepres-
sants
y/y (95%C11.2–2.8) vs. placebo and superior to placebo, insuf-
fcient
Mulrow 98 drugs) 1.2 (1.0–1.4) vs. antidepressants evidence re equivalence with
[21,22] antidepressants
Kim 99 [23] depression hypericum placebo and 6 RCT p/y/y/ Treatment response: RR 1.48 Hypericum more effective 
than
antidepres-
sants
y/y (95%C11.03–1.92) vs. placebo placebo and similarly effective 
as
and 0.98 (0.67–1.28) vs. 
antidepressants
low dose antidepressants; 
quality problems
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er
99 [24] antidepres-
sants
y/n 96; trials show effects better trials, but still insuff. evidence 
to
than placebo/similar to assess equivalence with
antidepressants antidepressants
Linde 98 & depression hypericum placebo and 27 RCT y/y/y/ Treatment response: RR 2.47 Hypericum more effective 
than
96 [25,26] antidepres-
sants
y/y (95%C11.69–3.61) vs. placebo placebo. Inadequate evidence 
to
and 1.01 (0.87–1.16) vs. assess equivalence with
antidepressants antidepressants
Volz 97 depression hypericum placebo and 15 p/p/n/ Most placebo-controlled trials A therapy with hypericum of 
mild
[27] antidepres-
sants
RCT/
CCT
n/n positive; similarly effective as 
(not adequately dosed) antide-
pressants
and moderate depression can 
be attempted. Further studies 
needed
Ernst 95 depression hypericum placebo and 11 RCT y/y/y/ Most of 8 placebo-controlled Hypericum is superior to pla-
cebo
[28] antidepres-
sants
y/n trials positive. 3 trials against 
standard medication with similar 
effects
and seems equally effective as 
standard medication
Volz 2000 mild to hypericum fluoxetine 17+9 n/y/n/ No direct comparison of Response rates are similar;
[29] mod. CCT y/n hypericum and fluoxetine findings difficult to interpret
depression available. Mean depression score 
(HAMD) reduction in hypericum 
trials 53%, in fluoxetine trials 
55%
because of the indirect com-
parison
Friede 98 anxiety in hypericum placebo, 8 RCT ?/y/y/ Trials collectively show reduc-
tion
Hypericum is effective for
[30] depressed 
p.
amitriptyline y/n of anxiety symptoms over place-
bo. Only 1 trial vs amitriptyline
depressed patients with anxie-
ty
Garlic (Allium sativum)
Lawrence cardiovasc. garlic mainly place-
bo;
45 RCT y/y/y/ 37 trials consistently show small Insufficient data to draw con-
clusion
2000 [31] risk factors no & other 
treatment
y/y short-term effects over placebo 
for cholesterol reduction. No 
consistent effects on blood pres-
sure, promising effects re 
platelet aggregation and fibriono-
lytic activity
regarding clinical cardiovascu-
lar outcomes. Garlic prepara-
tions may have small, positive, 
short-term effects on lipids
 
Stevinson hyperchol- garlic placebo 13 RCT y/y/y/ Pooled total cholesterol Available data suggest that gar-
lic is
2000 [32] esterolem-
ia
y/y reduction over placebo 0.41 superior to placebo. The size 
of the
(95% Cl -0.66 to -0.15) mmol/l; effect is modest. The use of 
garlic
when analysis restricted to high for hyperchol. is therefore of
quality trials 0.11 (-0.30 to 0.08) questionable value
Silagy 94 & cholesterol garlic placebo 16 RCT y/p/y/ Pooled cholesterol reduction Meta-analysis suggests positive
Neil 96 lowering y/y over placebo 0.65 (95% Cl 0.53– effects but reviewers are scep-
tic
[33,34] 0.76) mmol/l (low quality; own replication
negative)
Warshafsky cholesterol garlic placebo 5 RCT p/y/y/ Pooled cholesterol reduction Available evidence supports 
the
93 [35] lowering y/y over placebo 0.59 (95%Cl 0.44– use of garlic as one modality to
0.74) mmol/l decrease cholesterol levels
Silagy 94 lowering dried garlic placebo, other 8 RCT y/p/y/ Pooled reduction over placebo: Garlic maybe of some clinical 
use
Table 2: Systematic reviews of clinical trials of hypericum and garlic preparations (Continued)
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sion.
press. 5.0 (2.9–7.1) mm Hg Further research needed
Kleijnen 91 cardiovasc. garlic placebo 18 p/p/y/ Most studies with shortcomings. No clear conclusion drawn
[37] risk factors supplements RCT/
CCT
y/n The majority of trials with pos. 
results but inconsistent effect siz-
es
Kleijnen 89 cardiovasc. garlic & unclear 10 
RCT,
y/p/n/ All trials with severe Inadequate evidence to justify
[38] risk factors onions 8 CCT y/n shortcomings. Fresh garlic with supplementation, further re-
search
beneficial effcts, onions and needed
commercially available
supplements yielded
contradictory results
Jepson 97 lower limb garlic placebo 1 RCT y/y/y/ Walking distance not Insufficient evidence
[39] athero-
scler.
y/- significantly different between 
groups
legend see table 1
Table 3: Systematic reviews of clinical trials of herbal medicines (at least 2 reviews per herb)
Features
Author Indication Intervention Comparisons Studies 1/2/3/ Results Author's Conclusion
Year 4/5
Echinacea (Echinacea purpurea, angustifolia and pallida)
Barrett upper re-
sp.
echinacea placebo 13RC
T
y/p/y/ Overall quality modest. All 4 Echinacea may be beneficial for
99 [40] infections (incl. combi-
nations)
y/n prevention studies show only 
minor trends, 8 of 9 treatment 
studies with generally positive 
results
early treatment of acute upper respi-
ratory infections; little evidence to 
support the prolonged use for pre-
vention
Melchart common echinacea placebo, no 16 
RCT
y/y/y/ Minor effects in prevention and Echinacea extract can be efficacious
99 [41] cold (incl. treatment y/p treatment, promising effects in for the common cold, but evidence
combina-
tions)
early treatment. Heterogen. 
preparations
insufficient for recommendations
Melchart immuno- echinacea placebo, no 18 
RCT, 8
y/y/y/ Most studies low quality. Most Echinacea extracts can be
94 stimula-
tion
(incl. treatment CCT y/n studies show immunostimulat-
ing
efficacious immunostimulators, but
[42,43] combina-
tions)
effects evidence insufficient for recommen-
dations
Cranberries (Vaccinium macrocarpon)
Jepson urinary cranberries placebo 4 RCT y/y/y/ In 3 of 4 trials cranberries effec-
tive
Insufficient evidence, further research
98 [44] tract inf. 
(prevent)
y/n for at least one of the outcomes 
of interest
needed
Jepson urinary cranberries O 
RCT
y/y/-/ No trials meeting the inclusion No evidence available
98 [45] tract inf. -/- criteria
(treatm.)
Mistletoe (Viscum album)
Kleijnen cancer mistletoe placebo, no 11 y/y/y/ Most studies low quality. Most Insufficient evidence to recommend
Table 2: Systematic reviews of clinical trials of hypericum and garlic preparations (Continued)
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CCT
n/n studies show longer survival 
with mistletoe but not the best 
trial
mistletoe outside of clinical trials
Kiene 89 cancer mistletoe no treat-
ment,
2 RCT, 
33
y/n/n/ Most studies low quality. 9 of 12 Available evidence supports positive
[47,48] none CCT, 
11
y/n interpretable studies suggest effects of mistletoe
other positive effects on survival
studies
Peppermint (Mentha piperita)
Jailwala irritable 1. pepper-
mint
placebo 1. 3 
RCT
p/y/y/ Chinese herbal therapy trial rat-
ed
In both cases efficacy not clearly
2000* bowel oil 2. 1 
RCT
n/n as positive, one of three established
[49] syndr. 2. Chinese peppermint oil trials rated as
herbal positive
therapy
Pittler 98 irritable peppermint placebo, 8 RCT y/y/y/ Global improvement rates The role of peppermint oil for IBS
[50] bowel oil other y/y significantly higher compared to has not been established beyond
syndr. treatment placebo. Quality of trials doubt-
ful
reasonable doubt
Saw palmetto (Serenoa repens)
Boyle ben. Permixon® placebo, 11 
RCTs,
?/n/n/ peak urine flow 2.20 (95% Cl 
1.20–
Despite some limitations strong
2000 
[51]
prostate (saw other 2 UCS y/y 3.20) ml/s increase over place-
bo;
evidence that the extract tested has
hyperpla-
sia
palmetto) treatment significant decrease nocturia beneficial effects
Wilt 
2000
ben. saw palmet-
to
placebo, 14 
RCT
y/y/y/ Saw palmetto superior to place-
bo
Evidence suggests that saw
&98 prostate other (plac), y/y for nocturia, self rating, peak 
urine
palmetto improves urological
[52,53] hyperpla-
sia
treatment 5 RCT flow; similar effects as finas-
teride
symptoms and flow measures.
(oth-
er)
Further studies needed
legend see table 1
Table 3: Systematic reviews of clinical trials of herbal medicines (at least 2 reviews per herb) (Continued)
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Features
Author Indication Intervention Comparisons Studies 1/2/3/ Results Author's Conclusion
Year 4/5
Vogler 
99
various aloe placebo, oth-
er
6 
RCT,4
y/y/y/ Positive results for genital Promising results, but overall
[54] & no treat-
ment
CCT y/n herpes, psoriasis, hyper-lipi-
demia, diabetes; contradictory 
for wound healing
evidence insufficient
Pittler 
98
choles-
terol low-
ering
artichoke 
leave 
extract
placebo 1 RCT y/y/y/ Effects over placebo only in the More trials needed
[55] n/n subgroup of participants with
serum cholesterol > 210 mg/dl
Morse 
89
atopic evening placebo 9 ?/n/n/ Epogam significantly better No conclusion drawn
[56] eczema primrose oil
(Epogam)
RCT/
CCT
y/y than placebo for most outcomes
Vogler 
98
migraine feverfew placebo 5 RCT y/y/y/ Majority of trials favor feverfew Effectiveness has not been
[57] y/n over placebo established beyond reasonable
doubt
Ernst 
2000
nausea 
and
ginger root placebo, 6 RCT y/y/y/ 2 of 3 trials on postoperative Evidence promising but insufficient
[58] vomiting metoclopra-
mide
y/p nausea positive (best negative), 
trials on seasickness, morning 
sickness and chemotherapy-in-
duced nausea positive
to draw firm conclusions
Vogler 
99
various ginseng root 
extract
placebo, oth-
er
16 RCT y/p/y/ Contradictory results re. The efficacy of ginseng root extract
[59] treatment (1 y/n physical performance (7 trials), is not established beyond
trial) psychological function (5), reasonable doubt for any of these
immunomodulation (2), indications
positive results in diabetes and
herpes simplex (1 trial
respectively)
Pittler 
98
venous horse placebo, oth-
er
13 RCT y/y/y/ Significant effects over placebo horse chestnut seeds seem to be
[60] insuffi-
cieny
chestnut treatment y/n and similar effects compared to effective; further tials needed
seeds other treatments (confirmation, long-term results,
combination)
Pittler 
2000
anxiety kava placebo 7 RCT y/y/y/ All trials suggest superiority Available data suggest that kava is
[61] p/p over placebo; 3 trials with data a treatment option for anxiety.
for meta-analysis show sign. Further studies needed
superiority
Law-
rence
liver milk thistle placebo, oth-
er
33 
RCT,
y/y/y/ Variety of conditions studied, Efficacy is not established.
2000 
[62]
diseases & no treat-
ment
1 CCT y/y studies often poor quality. Possible benefit shown most
Mixed and inconsistent findings frequently for aminotransferases.
Ernst 99 muscu-
loskel.
Phytodo-
lor®
placebo, oth-
er
10 RCT y/p/y/ Placebo-controlled trials show The data suggest that the
[63] pain populus, treatments y/n superiority over placebo and combination is effective in the
fraxinus, similar effects as NSAIDs symptomatic treatment of
solidago muskuloskeletal pain
Mac-
Donald
ben. pros-
tata
rye grass placebo, oth-
er
4 RCT y/y/y/ Signif. improvement over Available evidence suggests that
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Our overview shows that a considerable number of sys-
tematic reviews on herbal medicines is available. In the
majority of cases the reviewers considered the available
evidence as promising but only very rarely as convincing
and sufficient as a firm basis for clinical decisions. The
methodological quality of the primary studies has been
criticized by many reviewers.
Our summary of the existing studies must be interpreted
with caution. What we performed is a systematic review
of systematic reviews which inherently bears a large risk
of oversimplification. Readers who want to reliably as-
sess the evidence for a given herb for a defined condition
should read the respective reviews. Our collection –
which to the best of our knowledge is complete up to
summer 2000 – is aimed at facilitating the access and
giving an idea of the amount of the available evidence.
Based on the increase of herbal medicine reviews in re-
cent years we expect that at least ten new publications
will become available in the year 2001.
Most of the currently available systematic reviews ad-
dress herbal preparations which are marketed and wide-
ly used in industrialized countries. However, the
widespread traditional use of herbs in the Third World is
rarely ever investigated and has not been subjected to
systematic reviews. The many herbs used in folk medi-
cine or other traditional uses of herbs (for example, hy-
pericum is used for a variety of ailments other than
depression including enuresis, diarrhoea, gastritis, bron-
chitis, asthma, sleeping disorders etc.) seem to be rarely
investigated. Furthermore, practitioners of herbal medi-
cine often combine different herbs and use unconven-
tional diagnostic approaches to adapt prescriptions to
single patients. It seems likely that these traditional
2000 & hyperpla-
sia
pollen therapy y/y placebo in subjective, but not Cernilton® is well tolerated and
Wilt 
2000
extract objective symptoms; no modestly improves subjective
[64,65] differences compared to symptoms. Further studies needed
tadenan and paraprost
Ernst 
2000
dermato-
logic
tea trea oil placebo, 
other
4 RCT y/y/y/ 2 trials vs. placebo positive, 3 Data promising but insufficient
[66] condi-
tions
treatment y/n trials vs. other treatments
similar effects
Stevin-
son
insomnia valerian 
root
placebo 9 RCT y/y/y/ Highly heterogeneous studies Available evidence is promising but
2000 
[67]
y/n with sometimes contradictory not fully conclusive. Further,
and inconsistent findings rigorous trials needed
Renfrew breast cabbage usual care 1 RCT y/y/n/ fewer women stopping breast Further research desirable
84 [68] engorge-
ment
leaves y/n feeding among those receiving 
cabbage leaves
Arm-
strong
atopic Chinese placebo 2 RCT y/y/n/ 2 positive studies by the same Evidence encouraging but
99 [69] eczema herbal y/n insufficient given the potential of
therapy treat analysis relevant side effects
Ernst 97 hypoglyc. all plants no treatment, 7 RCT, 
4
y/p/n/ Most studies low quality. Most Use of hypoglcemic plant remedies
[70] activity placebo, 
none
CCT, 
10
y/n papers report positive effects not supported by rigorous
UCS on a variety of plants research. Further studies required
Ernst 
2000
analgetic 
or
various placebo 18 RCT y/y/y/ Trials on evening primrose oil, The results suggest that several
[71] inflamm. y/n blackcurrant seed oil, borage herbal remedies have potential in
treatment oil, harpagophytum, willow alleviating the pain of rheumatic
bark, feverfew, and 3 diseases. More research urgently
combinations; almost all trials needed
positive
legend see table 1
Table 4: Systematic reviews of clinical trials of herbal medicines (Continued)
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relative to single herbal preparations due to the lack of fi-
nancial incentive for sponsors and due to methodological
problems.
Herbal medicines products are not, in general, subject to
patent protection. This reduces the motivation for drug
companies to invest in trials. Many of the existing herbal
medicine manufacturers are comparably small compa-
nies, often with limited research resources and expertise.
Maybe partly for these reasons, the quality of many older
herbal medicine trials is low. Furthermore, negative tri-
als which could threaten the company's survival might
not become published.
A fundamental problem in all clinical research of herbal
medicines is whether different products, extracts, or
even different lots of the same extract are comparable
and equivalent. This is a major issue in the expert re-
search community and a major obstacle to a reliable as-
sessment for the non-expert. For example, Echinacea
products can contain other plant extracts, use different
plant species (E. purpurea, pallida or angustifolia), dif-
ferent parts (herb, root, both), and might have been pro-
duced in quite different manners (hydro- or lipophilic
extraction). Pooling studies that use different herbal
products in a quantitative meta- analysis can be mislead-
ing. Health care professionals and patients considering
to prescribe or take a particluar herbal product should
check carefully whether the respective product or extract
has been tested in the trials included in a review. On the
health food store shelf the high quality, standardized
products used in the trials might not be available. Only a
herbal medicine expert can judge with some certainty
whether the results can be extrapolated to the product of
interest.
On the level of health care policies the available system-
atic reviews more often provide insight into the deficien-
cies of the evidence than guidance for decision making.
Trials on hard endpoints are very rarely available and ob-
servation periods have generally been short. The clinical
relevance of the observed effects is not always clear.
Herbal medicines are generally considered as compara-
bly safe. While this is probably correct case reports show
that severe side effects and relevant interactions with
other drugs can occur. For example, hypericum extracts
cause considerably fewer side effects than tricyclic anti-
depressants [92] but can decrease the concentration of a
variety of other drugs by enzyme induction [93]. Several
reviews summarizing side effects and interactions have
been published [94–98].
In conclusion, the systematic reviews collected for this
analysis are a good tool to get an overview of the available
evidence from clinical trials in the area of herbal medi-
cine. However, applying the findings to patients care is
problematic for those who are not experts in herbal med-
icine. In this case it might be better to directly search the
literature for clinical trials of the respective product.
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